The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma

NCT ID: NCT02525965

Last Updated: 2016-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

194 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Before the surgery, the investigators predict the risk of microvascular invasion (MVI) presence for the early-stage hepatocellular carcinoma according to the nomogram the investigators have created. Patients with a high risk of microvascular invasion were randomly chose to give the treatment of a wide resection margin, which establish an individualized anti-recurrence program based on the high-grade evidence-based medicine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although liver resection is still the first line of treatment for hepatocellular carcinoma (HCC) presently, 5-year overall recurrence rates \> 70%, the same with early-stage hepatocellular carcinoma, for some studies reported the rates \> 40%. Recurrence is also the first cause of death in these patients, so recurrence is the most important factors affecting surgical results of HCC. For the precaution of cancer recurrence, there are no proven techniques for clinical reference at present.

For now, there has been many controversies on the impact about the width of liver resection margin on curative effect. Poon has proven that there is no significant difference in recurrence rate between resection margin \> 1cm and resection margin \< 1cm. However, Shi et al published a randomized controlled trial: for patients with a solitary tumor, resection margin \> 2cm can reduce the recurrence rate after hepatectomy. This is also the only randomized clinical trial study which proves increaseing resection margin will benefit the clinical results at present. A meta analysis consist of 18 studies proves that whether the resection margin has a relationship with a benefit clinical result still needs a further verification.

On the other hand, because microvascular invasion (MVI) is the direct evidence of the micro metastasis in hepatocellular carcinoma, it will decrease recurrence rate for the patients with a high MVI risk, if the investigators increase the resection margin width during the surgery? Shanghai Eastern Hepatobiliary Surgery Hospital which the investigators affiliated with had ever conducted a retrospective analysis on consecutive 3263 patients with HCC hepatectomy, the results indicated that a wide resection margin(≥1cm)can benefit those patients with microvascular invasion , nevertheless, the benefit will not present if patients are without microvascular invasion.

Further and better proofs still needs to approval this consequence, of course. In the past,another study of the ours, published online in the Journal of the American Medical Association Surgery, established a nomogram to predict the presence of microvascular invasion in the early-stage hepatocellular carcinoma, it will efficiently predict the occurrence of microvascular invasion in the hepatocellular carcinoma (HCC) fulfilled the Milan criteria. In consideration of the above basis, the investigators will implement a randomized controlled trial to certificate whether it could really reduce the recurrence rate after liver resection for participants with a high MVI risk during the surgery, if the method participants chose is a wide resection margin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Wide resection margin Recurrence Early-stage hepatocellular carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Wide resection margin >1cm

Surgical removal of lesions choosing the method of wide resection margin \>1cm

Group Type EXPERIMENTAL

Wide resection margin >1cm

Intervention Type PROCEDURE

Surgical removal of lesions choosing the method of wide resection margin \>1cm

Narrow resection margin <1cm

Surgical removal of lesions choosing the method of narrow resection margin \<1cm

Group Type ACTIVE_COMPARATOR

Narrow resection margin <1cm

Intervention Type PROCEDURE

Surgical removal of lesions choosing the method of wide resection margin \<1cm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wide resection margin >1cm

Surgical removal of lesions choosing the method of wide resection margin \>1cm

Intervention Type PROCEDURE

Narrow resection margin <1cm

Surgical removal of lesions choosing the method of wide resection margin \<1cm

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients \> 18 years and \<=70 years of age.
* Diagnosed with HCC according to the criteria of American Association for the Study of Liver Diseases (AASLD).
* Fulfill the Milan criteria.
* High-risk of microvascular invasion (MVI).
* Nomogram score \>200.
* Performance status score is 0-1 before the surgery.
* Without or mild liver cirrhosis and the liver function is Child A class.
* Without any other treatments such as TACE、PEI、PRFA before the surgery.

Exclusion Criteria

* Patients with macro tumor thrombus or extrahepatic metastasis.
* Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction.
* Subjects accepting other trial drugs or participating in other clinical trials.
* Patients refuse to join our trial.
* Female with pregnancy or during the lactation period.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eastern Hepatobiliary Surgery Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ShenFeng

vice president of the Eastern Hepatobiliary Surgery Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shen Feng, MD

Role: STUDY_CHAIR

Eastern Hepatobiliary Surgery Hospital, Second Military Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eastern hepatobilliary surgery hospital

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shen Feng, MD

Role: CONTACT

Phone: 0086-021-25070805

Email: [email protected]

Wu Dong, MD

Role: CONTACT

Phone: 0086-021-25070765

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Shen Feng, MD

Role: primary

Wu Dong, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EHBHLRM-2015-8-10

Identifier Type: -

Identifier Source: org_study_id